ResMed (RMD) is back in focus after Frazier Healthcare Partners completed its acquisition of MatrixCare, the company’s residential care software subsidiary, with Jonathan Lujan appointed as MatrixCare’s new chief executive officer.

ResMed’s latest move comes after a mixed year for investors, with the share price down 5.49% year to date but showing a 24.08% 90 day share price return and a 54.84% total shareholder return over three years. However, the one year total shareholder return declined 13.72%, suggesting shorter term momentum has softened compared with the longer term record.

Compare this reshaping of ResMed’s portfolio with other health-focused stocks that have strong fundamentals using the curated list of solid balance sheet and fundamentals (53 results)

So is this sale telling you something meaningful about ResMed’s underlying cash generation and focus, or is it mainly reflecting a change in how investors feel about the stock after a choppy share price run into 2026?

Most Popular Narrative: 6.7% Undervalued

At a last close of $231.36, the most followed narrative for ResMed points to a fair value of about $247.93, suggesting the market price is lagging the modelled fundamentals.

Strategic investments in expanding the diagnosis and treatment funnel including acquisitions like VirtuOx, Ectosense, and Somnoware are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.

Read the complete narrative.

Want to see what is baked into that fair value for ResMed? The narrative leans heavily on steady revenue growth, firm margins, and a richer earnings multiple. The exact targets and timeframes behind those assumptions are where the story gets interesting.

Result: Fair Value of $247.93 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside narrative for ResMed could be challenged if ventilator component constraints and a potential Philips Respironics re entry both put pressure on pricing power and earnings expectations.

Find out about the key risks to this ResMed narrative.

Next Steps

If the mix of risks and optimism around ResMed feels finely balanced, consider acting while sentiment is still forming. You can stress test the positives yourself with the 4 key rewards

Looking for more investment ideas beyond ResMed?

If you stop at ResMed, you could miss other opportunities that match your style. Put a few minutes into broadening your watchlist and future you may thank you.

• Spot potential growth stories early by checking out carefully selected small companies in the 22 elite penny stocks with strong financials.
• Focus on value by reviewing companies with strong fundamentals that currently trade at what our models suggest is a discount using the 50 high quality undervalued stocks.
• Prioritise resilience by scanning for financially robust stocks with healthier balance sheets through the list of solid balance sheet and fundamentals (53 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.